Xolair is indicated as add-on therapy for the treatment of chronic spontaneous urticaria in adult and adolescent (12 years and above) patients with inadequate response to H1-antihistamine treatment.1
In the first update to the BAD chronic urticaria guidelines since 2007, join Dr John Reed and Dr Chris Rutowski (dermatology and allergy experts respectively) for their views on what they mean for your day-to-day practice.
Use the links below to jump to the individual videos:
High-dose antihistamines and ciclosporin are not licensed for the treatment of CSU.
A review of the new BAD guidelines for CSU and how they can be used to support up-dosing or switching to second-line treatment more quickly.
When to prescribe omalizumab over ciclosporin, and vice versa, for the second-line treatment of CSU, using specific patient markers to identify appropriate treatment.
An exploration of the value of testing IgE and BHRA before prescribing omalizumab versus delaying treatment.
How quickly to up-dose antihistamine, when high-dose antihistamine is not enough, and why monitoring patient response is key to decision making.
The steps to initiating omalizumab, emphasising the importance of patient-recorded outcome measures, reviewing patient response and stopping treatment where necessary.
A discussion of reported anaphylactic reactions in patients on omalizumab and the lack of evidence of this side effect in practice.
A review into the value of PROs and when to use them to support CSU treatment management decisions.
*Post hoc analysis of phase 3 studies2, omalizumab 300 mg significantly improved total DLQI scores vs placebo: ASTERIA I: mean decrease from baseline to week 12 of −10.3 vs −6.1 (p<0.0001); ASTERIA II: −10.2 vs −6.1 (p=0.0004); GLACIAL: −9.7 vs −5.1 (p<0.0001).
BAD, British Association of Dermatologists; BHRA: basophil histamine release assay; CSU: chronic spontaneous urticaria; IgE: immunoglobulin E; PRO: patient-reported outcome.
- Xolair® (omalizumab) 150 mg Summary of Product Characteristics.
- Finlay AY et al. J Eur Acad Dermatol Venereol 2017;31(10):1715–1721.